Arbutus Biopharma Corp Payments for Restructuring
Arbutus Biopharma Corp (ABUS) reported Payments for Restructuring of $1.16 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2019-11-06
- Arbutus Biopharma Corp payments for restructuring for the quarter ending 2019-09-30 was $321.00K.
- Arbutus Biopharma Corp payments for restructuring for the quarter ending 2019-06-30 was $374.00K, a 85.16% decline year-over-year.
- Arbutus Biopharma Corp payments for restructuring for the quarter ending 2019-03-31 was $466.00K, a 21.28% decline year-over-year.
- Arbutus Biopharma Corp payments for restructuring for the quarter ending 2018-12-31 was $526.00K.
- Arbutus Biopharma Corp payments for restructuring for fiscal 2018 was $3.47M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2019-09-30 | $321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $695.00K derived: sum of 2 quarters · filed 2019-11-06 | $1.16M 10-Q · filed 2019-11-06 | $1.69M derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $840.00K 10-Q · filed 2019-08-05 | $1.37M derived: sum of 3 quarters · filed 2019-08-05 | $1.19M derived: sum of 4 quarters · filed 2019-08-05 |
| 2019-03-31 | $466.00K 10-Q · filed 2019-05-06 | $992.00K derived: sum of 2 quarters · filed 2019-05-06 | $820.00K derived: sum of 3 quarters · filed 2019-05-06 | $3.34M derived: sum of 4 quarters · filed 2019-05-06 |
| 2018-12-31 | $526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $354.00K derived: sum of 2 quarters · filed 2019-03-07 | $2.87M derived: sum of 3 quarters · filed 2019-03-07 | $3.47M 10-K · filed 2019-03-07 |
| 2018-09-30 | -$172.00K 10-Q · filed 2018-11-07 | $2.35M derived: sum of 2 quarters · filed 2018-11-07 | $2.94M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $2.52M 10-Q · filed 2018-11-07 | $3.11M 10-Q · filed 2018-08-03 | ||
| 2018-03-31 | $592.00K 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |